Inclusion Criteria:

- Male or female patients

- Patients with acute lymphoblastic leukemia (ALL) undergoing first induction
chemotherapy within the GMALL-Elderly 1/2003 protocol

- Females of childbearing potential (less than 2 years post-menopausal) must be
surgically incapable of pregnancy, or practicing an acceptable method of birth
control with a negative pregnancy test (blood or urine) at baseline

- Understanding of the study's rationale and procedures documented in the patient's
informed consent

- Ability and agreement to comply with all study requirements

- Patient willing to attend hospital appointments for each visit (infusions will be
performed in hospital, under strict medical supervision).

Exclusion Criteria:

- Known hypersensitivity to amphotericin B or LAMB or any of its constituents, in
particular known history of anaphylactic reaction to amphotericin B or LAMB or any of
its constituents

- Signs or symptoms of IFI or previous proven or probable IFI in the medical history

- Evidence for pulmonary infiltrates in chest CT and/or x-ray of the chest (only when a
chest CT/x-ray is done at baseline)

- Estimated creatinine clearance (ECC) ≤ 60 mL/min (Cockcroft-Gault); in such cases the
body surface adjusted Modification Diet in Renal Disease (MDRD) glomerular filtration
rate (GFRMDRD) should be calculated. If the body surface adjusted GFRMDRD is above 60
mL/min, the patient can be included.

- Patient with moderate or severe liver disease as defined by AST, ALT or alkaline
phosphatase (AP) > 5 times the upper limit of normal (ULN), or bilirubin > 3 times
ULN

- Patients who are unlikely to survive more than 1 month

- Febrile patients (≥ 38.5°C)

- Patients who have received systemic antifungal therapy within 15 days prior to the
inclusion

- Any severe co-morbidity other than the underlying hematological disease (ALL), which
in the investigator's judgment may interfere with study evaluations or affect the
patient's safety

- Patients previously included in this study

- Patients who have taken any investigational drug within the last 30 days prior to
inclusion except drugs used according to the GMALL-Elderly/2003 protocol

- Patients who participate in another clinical trial except anti-cancer trials